How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Alexander Kriz
Advertisement
Alexander Kriz is Director at Executive Insight.
Articles by Alexander Kriz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
3
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
4
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
5
